Table 6 Clinical characteristics of... | American Society of Hematology

Table 6

Clinical characteristics of patients still on treatment, dasatinib-nilotinib group

Patient no.	Age, y	Duration of imatinib, mo	Dasatinib			Nilotinib
Patient no.	Age, y	Duration of imatinib, mo	Duration of nilotinib, mo	Best response	Reason off	Bcr-abl mutation before therapy	Dose, mg	Percentage of Ph-before therapy	Best response	Response duration, mo
2	60	48	17	CCyR	Grade II pleural effusion	Y253H	400 BID	100	MMR	21+
3	46	61	1.4	NR	Transformation	None	400 BID	100	CHR	25+
8	40	64	25	CHR	Grade II pleural effusion	Del 248-275	400 BID	100	PCyR	16+
9	18	26	9.6	mCyR	Grade II thrombocytopenia	None	400 QD	62	CHR	5.7+
11	57	22	11	mCyR	Loss CHR	F317L	400 BID	100	MMR	5.1+
13	46	26.4	34	CCyR	Loss CyR	V299L F486S	400 BID	100	MMR	23+
14	70	42	34	mCyR	Transformation	F317L	200 BID	100	NR	11.2+

Patient no.	Age, y	Duration of imatinib, mo	Dasatinib			Nilotinib
Patient no.	Age, y	Duration of imatinib, mo	Duration of nilotinib, mo	Best response	Reason off	Bcr-abl mutation before therapy	Dose, mg	Percentage of Ph-before therapy	Best response	Response duration, mo
2	60	48	17	CCyR	Grade II pleural effusion	Y253H	400 BID	100	MMR	21+
3	46	61	1.4	NR	Transformation	None	400 BID	100	CHR	25+
8	40	64	25	CHR	Grade II pleural effusion	Del 248-275	400 BID	100	PCyR	16+
9	18	26	9.6	mCyR	Grade II thrombocytopenia	None	400 QD	62	CHR	5.7+
11	57	22	11	mCyR	Loss CHR	F317L	400 BID	100	MMR	5.1+
13	46	26.4	34	CCyR	Loss CyR	V299L F486S	400 BID	100	MMR	23+
14	70	42	34	mCyR	Transformation	F317L	200 BID	100	NR	11.2+

QD indicates once daily; and BID, twice daily.